BACKGROUND: Prevention of venous thromboembolism after colorectal surgery remains challenging. National guidelines

 


Abstract

BACKGROUND: Prevention of venous thromboembolism after colorectal surgery remains challenging. National guidelines endorse thromboembolism prophylaxis for 4 weeks after colorectal cancer resection. Expert consensus favors extended prophylaxis after inflammatory bowel disease surgery. Actual frequency of prescription after resection remains unknown.

OBJECTIVE: To assess prescription of extended, post-discharge venous thromboembolism prophylaxis after resection in Michigan.

DESIGN: Retrospective review of elective colorectal resections within a statewide collaborative receiving post-discharge, extended duration prophylaxis.

SETTING: This study was conducted between October 2015 and February 2018 at an academic center.

PATIENTS: A total of 5722 patients (2171 with colorectal cancer, 266 with inflammatory bowel disease, 3285 with other).

MAIN OUTCOME MEASURES: We compared prescription of extended, post-discharge prophylaxis over time, between hospitals, and by indication.

RESULTS: Of 5722 patients, 373 (6.5%) received extended duration prophylaxis after discharge. Use was similar between patients undergoing surgery for cancer (282/2171, 13.0%) or inflammatory bowel disease (31/266, 11.7%, p=0.54), but was significantly more common for both compared with patients with other indications (60/3285, 1.8%, p<0.001).<0.001))<0.05)300 beds) were significantly more likely to prescribe extended duration prophylaxis for all conditions (both p<0.001),

LIMITATIONS: This study was limited by lack of assessment of actual adherence, small number of observed venous thromboembolism events, small sample of inflammatory bowel disease patients, and restriction to state of Michigan.

CONCLUSIONS: Use of extended duration venous thromboembolism prophylaxis after discharge is increasing, but remains uncommon in most hospitals. Efforts to improve adherence may require quality implementation initiatives or targeted payment incentives. See Video Abstract at http://links.lww.com/DCR/B193.

PMID: 32109912 [PubMed - as supplied by publisher]

16:01

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

16:01

In reply to this message

pubmed: caandvteortroorpul

Large and small platelets - (when) do they differ?


Related Articles

Large and small platelets - (when) do they differ?


J Thromb Haemost. 2020 Feb 28;:


Authors: Handtke S, Thiele T


Comments

Search This Blog

Archive

Show more

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

علاقة البيبي بالفراولة بالالفا فيتو بروتين

التغيرات الخمس التي تحدث للجسم عند المشي

إحصائيات سنة 2020 | تعداد سكَان دول إفريقيا تنازليا :

ما هو الليمونير للأسنان ؟

ACUPAN 20 MG, Solution injectable

CELEPHI 200 MG, Gélule

الام الظهر

VOXCIB 200 MG, Gélule

ميبستان

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

Kana Brax Laberax

TRIPASS XR تري باس

PARANTAL 100 MG, Suppositoire بارانتال 100 مجم تحاميل

الكبد الدهني Fatty Liver

الم اسفل الظهر (الحاد) الذي يظهر بشكل مفاجئ bal-agrisi

SEDALGIC 37.5 MG / 325 MG, Comprimé pelliculé [P] سيدالجيك 37.5 مجم / 325 مجم ، قرص مغلف [P]

نمـو الدمـاغ والتطـور العقـلي لـدى الطفـل

CELEPHI 200 MG, Gélule

أخطر أنواع المخدرات فى العالم و الشرق الاوسط

Archive

Show more